Tao Li

Mr. Tao Li


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
LWLi Wang
Li Wang
YZYongbo Zheng
Yongbo Zheng
SYShan Yin
Shan Yin
KLKun-Peng Li
Kun-Peng Li
TLTao Li
Tao Li
PZPing-yu Zhu
Ping-yu Zhu
Background: Changes in gut microbiota abundance have been linked to prostate cancer development. However, the causality of the gut-prostate axis remains unclear. Methods: The genome-wide association study (GWAS) data for gut microbiota sourced from MiBioGen (n = 14,306), alongside prostate cancer summary data from PRACTICAL (n = 140,254) and FinnGen Consortium (n = 133,164). Inverse-variance-weighted (IVW) was mainly used to compute odds ratios (OR) and 95% confidence intervals (Cl), after diligently scrutinizing potential sources of heterogeneity and horizontal pleiotropy via the rigorous utilization of Cochran's Q test, the MR-PRESSO method, and MR-Egger. We used meta-analysis methods in random effects to combine the Mendelian randomization (MR) estimates from the two sources. Results: The pooled analyses of MR results show that genus Eubacterium fissicatena (OR = 1.07, 95% CI 1.01 to 1.13, P = 0.011) and genus Odoribacter (OR = 1.14, 95% CI 1.01 to 1.27, P = 0.025) were positively associated with prostate cancer. However, genus Adlercreutzia (OR = 0.89, 95% CI 0.83 to 0.96, P = 0.002), Roseburia (OR = 0.90, 95% CI 0.83 to 0.99, P = 0.03), Holdemania (OR = 0.92, 95% CI 0.86 to 0.97, P = 0.005), Flavonifractor (OR = 0.85, 95% CI 0.74 to 0.98, P = 0.024) and Allisonella (OR = 0.93, 95% CI 0.89 to 0.98, P = 0.011) seems to be a protective factor for prostate cancer. Sensitivity analysis found no significant heterogeneity, horizontal pleiotropy, or reverse causal links in all causal associations. Conclusion: This MR study lends support to a causal relationship between genetically predicted gut microbiota and prostate cancer. Research on the gut-prostate axis, along with further multi-omics analyses, holds significant implications for the prevention and treatment of prostate cancer.

6 February 2026 in Medicine
Verified
Journal Article
Open access
EBEr Hao Bao
Er Hao Bao
YYYang Yang
Yang Yang
TLTao Li
Tao Li
YLYuchen Li
Yuchen Li
YLYing Liu
Ying Liu
PHPeng Hao
Peng Hao
To identify second primary malignancies (SPMs) death risk factors in prostate cancer (PCa) survivors and high-risk PCa patients for SPMs. With improved PCa survival, there’s a growing need to study second SPMs in PCa survivors. PCa patients from 2004 to 2015 in the surveillance, epidemiology, and end results database were screened for SPM risk. The Fine and Gray competing risk model identified SPM mortality risk factors via univariate and multivariate analyses. A competing risk nomogram predicted 3-, 5-, and 10-year SPM mortality risk, stratifying patients by total scores for risk assessment. Model performance was assessed using the correlation index, receiver operating characteristic curve, calibration curve, and area under the curve. SPM-diagnosed PCa patients (2004–2015) were split into a 7:3 training (n = 31,435) and validation set (n = 13,472). The nomogram included 12 factors: age, chemotherapy, radiation, Gleason score, race, grade, marital status, tumor size, surgical site, surgery/radiation sequence, scope, and stage. C–index values were 0.70 (se: 0.001) and 0.684 (se: 0.002) in training and validation, respectively, indicating high discriminative power. The 3-, 5-, and 10-year area under the curves in training were 0.75 (95% confidence interval (CI): 0.72–0.77), 0.73 (95% CI: 0.72–0.75), and 0.72 (95% CI: 0.7–0.73), and in validation were 0.7 (95% CI: 0.65–0.74), 0.7 (95% CI: 0.67–0.73), and 0.71 (95% CI: 0.69–0.73), respectively, showing good predictive accuracy. The calibration curve confirmed model fit. A competing risk model predicts SPM mortality in PCa survivors, aiding high-risk patient identification and guiding survival-oriented treatment and follow-up strategies.